Helius Medical Technologies Inc Class A (HSDT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Helius Medical Technologies Inc Class A stock (HSDT) is currently trading at $2.16. Helius Medical Technologies Inc Class A PS ratio (Price-to-Sales) is 114.47. Analyst consensus price target for HSDT is $4.00. WallStSmart rates HSDT as Sell.
- HSDT PE ratio analysis and historical PE chart
- HSDT PS ratio (Price-to-Sales) history and trend
- HSDT intrinsic value — DCF, Graham Number, EPV models
- HSDT stock price prediction 2025 2026 2027 2028 2029 2030
- HSDT fair value vs current price
- HSDT insider transactions and insider buying
- Is HSDT undervalued or overvalued?
- Helius Medical Technologies Inc Class A financial analysis — revenue, earnings, cash flow
- HSDT Piotroski F-Score and Altman Z-Score
- HSDT analyst price target and Smart Rating
Helius Medical Technologies Inc Class A
📊 No data available
Try selecting a different time range
Smart Analysis
Helius Medical Technologies Inc Class A (HSDT) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Helius Medical Technologies Inc Class A (HSDT) Key Strengths (1)
Revenue surging 1267.00% year-over-year
Supporting Valuation Data
Helius Medical Technologies Inc Class A (HSDT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 114.5x annual revenue
Very expensive at 25.1x book value
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 30.09%
Supporting Valuation Data
Helius Medical Technologies Inc Class A (HSDT) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 1267.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (114.47), Price/Book (25.15) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -344.30%, Operating Margin at -704.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -344.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1267.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HSDT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HSDT's Price-to-Sales ratio of 114.47x trades at a deep discount to its historical average of 259.2x (47th percentile). The current valuation is 90% below its historical high of 1132.2x set in Mar 2021, and 1237% above its historical low of 8.56x in Apr 2020. Over the past 12 months, the PS ratio has expanded from ~33.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Helius Medical Technologies Inc Class A (HSDT) · FINANCIAL SERVICES › ASSET MANAGEMENT
The Big Picture
Helius Medical Technologies Inc Class A is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 941,000 with 1267% growth year-over-year.
Key Findings
Revenue growing at 1267% YoY, reaching 941,000. This pace significantly outperforms most ASSET MANAGEMENT peers.
Spending 91% of revenue (858,000) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Helius Medical Technologies Inc Class A maintain 1267%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor ASSET MANAGEMENT industry trends, competitive moves, and regulatory changes that could impact Helius Medical Technologies Inc Class A.
Bottom Line
Helius Medical Technologies Inc Class A is a high-conviction growth story with revenue accelerating at 1267% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Helius Medical Technologies Inc Class A(HSDT)
NASDAQ
FINANCIAL SERVICES
ASSET MANAGEMENT
USA
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing and acquiring non-invasive technologies for the treatment of symptoms caused by neurological diseases or trauma. The company is headquartered in Newtown, Pennsylvania.